STAT3 and glioblastoma: We showed that a CTRP8‐RXFP1‐STAT3 signaling axis protects GBM cells against alkylating DNA base damage of DNA‐alkylating agent temozolomide (TMZ), the standard chemotherapeutic drug for the treatment of GBM patients.